Rubicon Genomics ThruPLEX Plasma-Seq Kit
Rubicon Genomics has launched its ThruPLEX Plasma-seq kit for the preparation of DNA libraries to analyze cell-free DNA found in plasma and other biofluids. The new kit is designed for Illumina next-generation sequencing platforms and has been evaluated by researchers at the Karolinska Institute and Cancer Research UK.
ThruPLEX Plasma-seq has a simple and fast workflow, requiring only three steps in a single tube and two hours of time, with no purification or sample transfers, and yields highly reproducible NGS libraries from less than 1 nanogram and up to 30 nanograms of cell-free DNA in plasma. The optimized repair and ligation chemistries and a modified protocol provide higher library diversity at low input amounts and broad and consistent GC coverage, Rubicon said. The kit is intended for use with plasma samples for applications including analysis of circulating tumor DNA using whole-genome, whole-exome, and targeted gene sequencing, as well as for non-invasive prenatal testing.
PierianDx Clinical Genomicist Workstation
PierianDx has released a new version of its Clinical Genomicist Workstation software. According to the company, version 3.0 includes a new exome sequencing workflow that meets guidelines set by the American College of Medical Genetics and Genomics. The updated tool leverages the company's database of genomic variants and its internally developed scoring algorithm to help researchers make sense of variants found in somatic cancer samples as well as in constitutional assays.
Amplion Biomarker Engine
Amplion has launched Biomarker Engine, a proprietary platform for rapidly gathering, filtering, and annotating biomarker information. The platform is an end-to-end workflow tool that has modules for pulling in unstructured and structured data, filtering and highlighting the data, annotating the data, and learning from the annotations. The biomarker engine uses natural language processing and machine learning. It is being deployed initially in BiomarkerBase to expand the coverage of biomarkers in clinical trials, said Amplion in a statement.
For more recently launched products and services, please see the New Products page on our website.